Corneal Collagen Crosslinking or CXL, is a treatment that works by strengthening corneal tissue to halt the bulging of the eye’s surface. The goal of this treatment is to stop the progression of keratoconus, and thereby prevent further deterioration in vision and the need for corneal transplantation. While this doesn’t correct or reverse keratoconus, it has been shown to significantly strengthen the cornea to keep it from getting worse.
The treatment is currently in F.D.A. clinical trials but is available in the European Union and many other countries. A patient with keratoconus who needed to wear contact lenses prior to CXL would still need to wear them after the treatment, but should experience less need to change the lens prescription.
NOTE: SynergEyes is not involved with the research and development nor commercialisation of corneal crosslinking.